Day 3, September 29

Funding and Partnering and Accelerating Development

Supply & Logistics
09:00

Chair’s opening remarks

Immune Profiling
09:00

Chair’s opening remarks

Cancer & Immunotherapy
09:00

Chair’s opening remarks

Respiratory
09:00

Chair's opening remarks

Bioprocess & Manufacture
09:00

Chair's opening remarks

Partnerships
09:00

Chair’s opening remarks

Hansilla Alaigh, Director, External Development, Emergent Biosolutions

Risk Assessment and Communication of Safety

Clinical trial logistics and product planning

Keynotes

Checkpoints & Combinations

RSV Vaccines Pipeline Update

Global Health Preparedness Strategy

Incorporating innovation to vaccine trials

Vaccine Bioprocessing Trends and Challenges

The Animal Health Business

Vaccine Safety
09:10

Panel: Mandatory vaccination policies around the world, are they working?

  • What has been the impact of the introduction of mandatory vaccination and other policies globally?
    • Has it had a positive impact overall or has it worsened polarization?
  • What have been the most successful strategies for communication?
  • Medical and religious exemptions
  • What is the relationship between the forcefulness of a policy and its impact on the rate of vaccination?
  • Using big data to analyze the spread of misinformation?
Cancer & Immunotherapy
09:10

Update on approaches to the development of clinical combination therapies

  • What are the fundamental principles of combination science?
  • Huge amounts of data have been generated from combination studies, how do you analyze these?
Clinical Development
09:10

Clinical trials of the future

  • Use of real-world evidence for vaccine efficacy
  • How to get information from the field to a database
  • Regulatory perspective in new development areas
Todd Wilson, Director, Early Clinical Development, GSK Vaccines
Bioprocess & Manufacture
09:10

How to teach an old dog new tricks: Application of an ageing approach to Life cycle management of a vaccine

Veterinary
09:10

Panel: The Future of the Animal Health Business

  • Discussing the emerging trends in animal health & biologics (companion and production animals)
  • The emergence of human health technologies in the animal health space; Are these technologies too expensive to implement in animal health?
  • The importance of establishing strong collaboration/partnerships for advancing animal health innovation
  • What about emerging markets? - Finding success in Latin America, China & India etc.
Cancer & Immunotherapy
09:40

Panel: Targeted approaches to combinations, what’s working?

  • What strategies can we use to identify the best combinations?
    • Using immunology as a guide?
    • Combinations of any active compound?
  • What are the major mechanisms we need to focus on?
  • How successful have targeted combinations been so far?
    • IO-IO/ IO-Non-IO combos / Targeting the TME / Angiogenesis inhibitors / Standard of care agents
  • What are the best biomarkers for combination studies?
  • What major challenges remain?
Bioprocess & Manufacture
09:40

Interactive panel: Unique rapid production opportunities and challenges that face RNA delivery and manufacture

  • Why and where will it make a difference?
  • How is it different to DNA vaccines?
  • What are the unique challenges and advantages of RNA vaccine?
  • How will RNA vaccines help in an outbreak like SARS-CoV-2? Can the scale-up/volume be big enough?
  • Does the speed and dosage have an effect on the overall quality of the vaccine?
Frederic Krohn, Director Business Development, CureVac

Analysing Response Across Different Groups

Disruptive Technologies in the Animal Health Space

Supply & Logistics
10:10

Managing the logistics of clinical trial start up processes

10:40

Networking Coffee Break

Vaccine Distribution

Target Discovery & Cancer Vaccines

Improving Clinical Performance in Respiratory Pathogens

Vaccine Development Processes & Global Health

Developing a Vaccine Revolution Against Infectious Diseases

Vaccine Safety
11:40

Joint presentation: Improving the ways that we engage with individuals around immunization: development and implementation of new and existing tools

·Should we be using a single vs. bundle approach to improve vaccine uptake? Or are we missing the point when it comes to improving coverage?(25min) Dr Holly Seale·Effective communication for promoting immunization uptake(25min) Professor John Parrish-Sprowl·Q&A (10 min)
Supply & Logistics
11:40

End-to-end supply; examples of deviations and solutions to overcome them

Immune Profiling
11:40

Omics studies in vaccine trials to deduce markers & mechanisms of protection for effective immunity

  • Analysis of differences in response between resource rich and resource poor areas; what can we learn from this?
Supply & Logistics
12:10

Can we achieve global harmonization of regulatory requirements for vaccines

  • Managing regulatory requirements and timelines while rolling out vaccine globally
  • Variability of assays and tests required internationally
  • Practicalities are very challenging – how do big pharma manage this?
  • Insurance of process control – what will satisfy regulatory bodies downstream?
  • When and how should you engage with regulatory bodies
Emerging and Infectious
12:10

AV7909 Next-generation Anthrax vaccine: Progress towards licensure

Josh Reece, Director Of Product Development, Emergent Biosolutions
Bioprocess & Manufacture
12:10

CanSino’s adenovirus-based viral vector technology platform and its applications in vaccine development

Helen Huihua Mao, Senior Vice President, CanSino Biologics Inc.

Informing Next Generation Vaccines

New Platform Derived Vaccines on Priority Pathogens

Clinical Development
12:40

Overcoming challenges in seasonal vaccine studies

13:10

Networking Lunch & Poster Session

Vaccine Safety Case Studies & Surveillance

A Deep Dive into Successful Partnering

Vaccine Safety
14:40

Panel: Unravelling dengue vaccine safety concerns: To what extend could they have been predicted?

  • Use of controlled human infection models
  • Need for complete assessment of viremia induced by the vaccine
  • The importance of balanced infectivity in live attenuated vaccines and balanced efficacy across age groups and sero-status
  • Surveillance:
    • Need for improved surveillance systems where dengue vaccine is introduced
    • How long should active surveillance continue?
    • Collection of blood samples – baseline & routinely scheduled collections
Supply & Logistics
14:40

Reducing timelines and costs of vaccine shipments

Bioprocess & Manufacture
14:40

Increasing production of live viral vaccines and vectors with novel bioreactor technologies

  • A historical perspective on adherent and non-adherent live-virus vaccine production and how recent advances in bioreactors allow for greater productivity and reduced costs per dose
Partnerships
14:40

Afternoon Chair’s Opening Remarks

Technology & Cold Chain

Broadly Protective and Pandemic Influenza Vaccines Updates

Immune Profiling
15:10

Interactive Discussion: How can we use data to inform next generation vaccines?

  • Exploring immune profiling platforms to accelerate and de-risk vaccine development
  • Can modelling immune responses outside the body human help to do this?
  • How can we use big data to inform next generation vaccines?
Cancer & Immunotherapy
15:10

Using AI to design neoantigen cancer vaccines

Emerging and Infectious
15:10

Using the ExpreS2 protein production platform towards a COVID-19 (SARS-CoV-2) Coronavirus vaccine development programme

Veterinary
15:10

Current status of rift valley fever vaccine development

  • Challenges and strategies for developing efficacious rift valley fever vaccines

Vaccine Pipeline Updates of Highly Infectious Diseases

Big Data

Vaccine Delivery & Manufacturing

Supply & Logistics
15:40

Minimising the impact of temperature deviations - vial drying to reduce need to take vaccine products out of cold chain

Partnerships
15:40

Success case study 3 - How to fund and develop vaccine for neglected tropical diseases

16:10

Networking Coffee Break

Bioprocess & Manufacture
16:35

Chair’s opening remarks

David Hipkiss, Chief Executive Officer, Enesi Pharma Limited

Improving Vaccine Uptake with Innovative Delivery Platforms

Vaccine Safety
16:40

Post-marketing assessment of vaccine safety in pregnancy

  • Key issues surrounding post-marketing safety surveillance for vaccines used during pregnancy
  • Update on changes in recently published Post-approval Pregnancy Safety Studies
Supply & Logistics
16:40

Ensuring the effective supply of temperature-sensitive vaccines for military personnel

Veterinary
16:40

Overcoming manufacturing challenges in the veterinary vaccine industry

  • Designing and commissioning high throughput manufacturing facilities
  • Facility and equipment design suitable for campaign production
  • Use of appropriate disposable technologies
  • Improving antigen yield through process optimization

Exploring trials in different populations

Vaccine Safety
17:10

Vaccine safety surveillance: what can we do to improve surveillance studies and databases?

  • What are the benefits of RCTs and large databases and how can they be improved?
    • How might it be enhanced?
  • How do we decide which signals are meaningful?
    • What is the existing infrastructure to evaluate signals
    • What processes are being added to speedup signal detection?
  • The need for better databases in LMICs – how do you recognize safety signals? How can they be implemented?
    • What international efforts are ongoing?
    • What is pharma doing to enhance pharmocovigilance
  • Evaluating vaccine safety in pregnant women and other at-risk populations
    • How can safety be monitored effectively in pregnant women and their offspring?
    • Emphasis on ways to increase the availability of vaccines for pregnant women
Bioprocess & Manufacture
17:55

How do different routes of delivery influence the immunological outcome?

  • Effectiveness and usability
18:10

Close of Congress

last published: 24/Mar/20 14:25 GMT